Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Go back to Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital| (NASDAQ: ALZN) | Delayed: 1.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.22 | 52 Week High | $ | |||
| Open | $1.22 | 52 Week Low | $ | |||
| Day High | $1.22 | P/E | N/A | |||
| Day Low | $1.22 | EPS | $ | |||
| Volume | 494 | |||||
